The latter were reversed by flecainide at RyR-blocking concentrations specifically in RyR2-P2328S as opposed to wild-type hearts, suggesting a basis for its recent therapeutic application in CPVT. This evidence concerns the gene RYR1 and catecholaminergic polymorphic ventricular tachycardia.